u/bruno_dumitru

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.

Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.

if a clinic will not name the facility, that is your answer

Who is the prescriber, and are they the same organisation as the pharmacy?

A test transaction costs one extra network fee and verifies the address, the network and the recipient’s crediting process before the main amount moves.

Correction: that gives 60 units, not what you have written. 10mg into 3mL is 3.33mg/mL and the division follows from there.

Yes — a logger in the box turns a fortnight of speculation into a chart.

That only works if the fill weight is exactly the label weight, and it usually is not exactly anything.

Contemporaneous records do not drift; reconstructed ones do, and the drift is systematic rather than random because memory smooths.

Do you have the mass spectrum?

Regional stock changes the question rather than answering it: shorter lanes mean less exposure and fewer variables, which is why the warehouse question is worth asking before ordering in summer.

Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.

What concentration did you actually reconstitute at, rather than what did you intend to?

erez_perrin has the units point exactly right. They are a volume on the barrel and nothing else.

The transaction hash is the canonical receipt: it is public, verifiable by either party, and it is what a support query should quote.

Which network, exactly?

Aim the stream down the wall of the vial rather than into the cake. Reconstitution is a solubility problem, not a mixing problem, and mechanical shear does nothing helpful.

compounded is not generic, there is no equivalence claim

units are a volume on a U-100 syringe, not a dose

phase 3 is where the comparison becomes fair

Agreed, and it is why the oral peptide comparison keeps misleading people.

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.

Same conditions each time for the weigh-in?

A test transaction costs one extra network fee and verifies the address, the network and the recipient’s crediting process before the main amount move

Disagreeing here: that is a network fee at a busy hour and it is not the supplier’s doing.

Not convinced. A warm pack on day six is expected behaviour from a pack designed for four.

if the maths gives you a fraction of a unit, change the concentration

the column you will wish you had is sleep

Gel packs are designed for a duty cycle. A liquid pack at the end of a longer-than-expected transit is a pack behaving as specified, not evidence of an excursion in the vial.

I would not extrapolate a mechanism from a model system to a person in one step, which is what that comment does.

Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.

A token symbol identifies an asset, not a network. The same symbol commonly exists on several chains with incompatible address formats, and sending across that boundary is generally unrecoverable.

Disagree with the "more water is safer" framing. It is not safer, it is just a different number to divide by.

Careful. Regulatory status differs by jurisdiction and has changed; a confident global statement is going to be wrong somewhere.

transit temperature is a distribution, not a number

Cosigning on cross-border prescriptions. The rules exist and they are narrower than the summaries suggest.

Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.

Agreed. Network first, address second, amount third, and in that order every time.

Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.

Aim the stream down the wall of the vial rather than into the cake. Reconstitution is a solubility problem, not a mixing problem, and mechanical shear does nothing helpful.

reimbursement is national, not European, and that is the whole board

Correcting myself upthread: the criterion I quoted was updated for this year.

A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.